Home / Fact sheets / Romania / Cervical qualitative data

Country fact sheet: Romania

CERVICAL CANCER SCREENING PROGRAMME

Reporting year for qualitative data: 2016
Source of qualitative data: Other (EU Report 2017)

There is a pilot project:
  • Starting year: December 2020
  • Ending year: December 2023
  • Primary test: HPV DNA testing
  • Sample size: 170.000 women (30 to 64 years)
  • Location: Cluj county

Organization of screening

An individual/team/institution responsible to coordinate the programme: Yes
Dedicated budget for screening programme: Yes
Documented cancer screening policy: Yes
Nature of documentation of the policy: Recommendation
Year programme was initiated: 2012
Programme introduction was preceded by a pilot: -
Screening tests provided free of charge: Yes
Diagnostic tests provided free of charge: -
Treatment services provided free of charge: -

Information system and data collection

System that collects data: Aggregated
   • Identification of eligible population: -
   • Screening participation: -
   • Screening test results: -
   • Further assessment: -
   • Final pathology diagnosis: -
   • Cancer staging: -
   • Treatment: -
The information system exists at national or sub-national level: Individual: Unknown
Aggregated: Unknown
The information system collects data outside the programme (opportunistic screening/private sector): -
Cancer screening data is linked with population-based cancer registry (PBCR): Yes

Screening protocol

A screening protocol or guideline: -
Year of published/updated protocol: -
Target age (min-max) and screening interval [months] for each test: Cytology (25-64 years / [60 months])
Triaging test used: -
Self-collection HPV recommended: -
"Screen and treat" included in the protocol: -
Treatment modality for "screen and treat": -

Invitations for screening and further assessment

Initiatives to create population awareness by the Health Ministry/Health Authority: -
Invitations to eligible population: Yes
Source of the eligible individuals identified:
Method of invitation: Other (Oraly by GP)
Screening kit included with the invitation: No
Screen positive individuals actively contacted for further assessment: No
Individuals with a precancer or cancer diagnosis actively contacted: -

Quality Assurance (QA) of screening activities

Documented standard operating procedure/policy for QA: -
An individual/team/institution responsible for QA: Yes
Accreditation of lab services: -
Accreditation of pathology services: -
Documented performance indicators: -
Reference standards for performance indicators: -
Evaluation reports published in the last five years: No

Performance indicators

Reporting year for quantitative data: 2016
Source of quantitative data: Report (EU Report 2017)
Age range and regional limitation if applicable: All ages
Invitation coverage (%):
Participation rate (%): 14.2
Examination coverage (%):
Completeness of data related to screening test results (%):
Completeness of data related to further assessment results (%):
Further assessment (Colposcopy referral) rate (%):
Further assessment participation rate (%):
Detection rate for CIN2+ (x 1000):
Detection rate for CIN3+ (x 1000):
Detection rate for invasive cancer (x 1000):
Positive Predictive Value of abnormal screening test to detect CIN2+ (x 1000):
Positive Predictive Value for CIN3+ (x 1000):
Positive Predictive Value for invasive cancer (x 1000):
More quantitative data (2012-2015/Cytology)


Check also the following factsheets: Romania, Breast, Colorectal